Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report

Trastuzumab deruxtecan (T-DXd) is used to treat human epidermal growth factor receptor 2-positive advanced breast cancer. Interstitial lung disease (ILD) is a severe adverse event associated with T-DXd. Current guidelines recommend permanent discontinuation of T-DXd after Common Terminology Criteria...

Descripción completa

Detalles Bibliográficos
Autores principales: de Weger, Vincent A., Schutte, Tim, Konings, Inge R.H.M., Menke-van der Houven van Oordt, Catharina Willemien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625870/
https://www.ncbi.nlm.nih.gov/pubmed/37926069
http://dx.doi.org/10.4048/jbc.2023.26.e38

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625870/
https://www.ncbi.nlm.nih.gov/pubmed/37926069
http://dx.doi.org/10.4048/jbc.2023.26.e38

Ejemplares similares